scholarly journals A Clinical Case Study on the Long Term Respiration Management of Amyotrophic Lateral Sclerosis Patient with Respiratory Failure

2014 ◽  
Vol 31 (3) ◽  
pp. 67-73 ◽  
Author(s):  
Jong Cheol Lee ◽  
Ho Hyun Jeong ◽  
Eun Hye Cha ◽  
Man Yong Park ◽  
Tae Ho Kim ◽  
...  
Keyword(s):  
Amyotrophic Lateral Sclerosis ◽  
Respiratory Failure ◽  
Clinical Case ◽  
Amyotrophic Lateral Sclerosis Patient ◽  
Clinical Case Study ◽  
Lateral Sclerosis

Long-term management of respiratory failure in amyotrophic lateral sclerosis

1982 ◽  
Vol 12 (1) ◽  
pp. 18-23 ◽  
Author(s):  
Edward D. Sivak ◽  
W. Terry Gipson ◽  
Maurice R. Hanson
Keyword(s):  
Amyotrophic Lateral Sclerosis ◽  
Respiratory Failure ◽  
Term Management ◽  
Lateral Sclerosis

scholarly journals Neuroregenerative Rehabilitation Therapy with long-term Lithium in a Male Amyotrophic Lateral Sclerosis Patient: A Case Report.

2019 ◽  
Vol 6 (2) ◽  
pp. 4337-4344
Author(s):  
Alok Sharma ◽  
Hemangi Sane ◽  
Radhika Pradhan ◽  
Amruta Paranjape ◽  
Nandini Gokulchandran ◽  
...  
Keyword(s):  
Amyotrophic Lateral Sclerosis ◽  
Mononuclear Cells ◽  
Cellular Therapy ◽  
Amyotrophic Lateral Sclerosis Patient ◽  
Autologous Bone Marrow ◽  
Rehabilitation Therapy ◽  
Novel Approach ◽  
Als Patients ◽  
Lateral Sclerosis

Various cellular therapies are being increasingly investigated for the treatment of Amyotrophic Lateral Sclerosis (ALS), a progressive neurodegenerative disease with selective loss of anterior horn cells. Lithium is known to enhance the potency of transplanted cells, while being well tolerated by ALS patients. Additionally, rehabilitation significantly improves outcomes in various neurodegenerative disorders. We present a 47-year-old male patient suffering from ALS for 2 years, whose treatment involved intrathecal transplantation of autologous Bone Marrow-derived Mononuclear Cells and long-term Lithium, followed by multidisciplinary neurorehabilitation, and standard Riluzole treatment. ALS-FRSr score improved from 39 to 41; FIM remained stable at 101; 6MWT distance improved from 396 m to 480 m and Berg Balance score remained stable at 56 over a span of 18 months. Symptomatic improvements were seen in speech, swallow, stamina, walking and muscle strength; fasciculations and cramps reduced drastically. The highlight of this case is the maintenance of the patient’s condition in view of a degenerative prognosis. Cellular therapy along with long term Lithium and holistic rehabilitation, in addition to standard Riluzole treatment- together termed as Neuroregenerative Rehabilitation Therapy- is a novel approach for halting disease progression and qualitatively improving living conditions for ALS patients and caregivers alike.

The Variable Nature of Stuttering: A Clinical Case Study

1995 ◽  
Vol 22 ◽  
pp. 29-35
Author(s):  
Jennifer Gutierrez ◽  
Anthony Caruso
Keyword(s):  
Clinical Case ◽  
Clinical Case Study ◽  
Variable Nature

Rehabilitation treatment associating maxillary atresia and missing superior incisors – clinical case study report

2017 ◽  
Vol 10 (38) ◽  
pp. 78-83
Author(s):  
João Batista de Paiva ◽  
Daniele Sigal Linhares ◽  
José Rino ◽  
Lindalva Gutierrez
Keyword(s):  
Clinical Case ◽  
Rehabilitation Treatment ◽  
Clinical Case Study ◽  
Study Report ◽  
Case Study Report

scholarly journals Improved Long-Term Survival with Edaravone Therapy in Patients with Amyotrophic Lateral Sclerosis: A Retrospective Single-Center Study in Japan

2021 ◽  
Vol 14 (8) ◽  
pp. 705
Author(s):  
Hideki Houzen ◽  
Takahiro Kano ◽  
Kazuhiro Horiuchi ◽  
Masahiro Wakita ◽  
Azusa Nagai ◽  
...  
Keyword(s):  
Amyotrophic Lateral Sclerosis ◽  
Rank Test ◽  
Positive Pressure ◽  
Control Group ◽  
Single Center ◽  
Term Survival ◽  
Long Term Survival ◽  
Kaplan Meier ◽  
Lateral Sclerosis

Reports on the long-term survival effect of edaravone, which was approved for the treatment of amyotrophic lateral sclerosis (ALS) in 2015 in Japan, are rare. Herein, we report our retrospective analysis of 45 consecutive patients with ALS who initially visited our hospital between 2013 and 2018. Of these, 22 patients were treated with edaravone for an average duration of 26.6 (range, 2–64) months, whereas the remaining patients were not treated with edaravone and comprised the control group. There were no differences in baseline demographics between the two groups. The primary endpoint was tracheostomy positive-pressure ventilation (TPPV) or death, and the follow-up period ended in December 2020. The survival rate was significantly better in the edaravone group than in the control group based on the Kaplan–Meier analysis, which revealed that the median survival durations were 49 (9–88) and 25 (8–41) months in the edaravone and control groups, respectively (p = 0.001, log-rank test). There were no serious edaravone-associated adverse effects during the study period. Overall, the findings of this single-center retrospective study suggest that edaravone might prolong survival in patients with ALS.

Sign in / Sign up

Export Citation Format

Share Document